Kenji Kabashima

36.5k total citations · 17 hit papers
483 papers, 22.4k citations indexed

About

Kenji Kabashima is a scholar working on Dermatology, Immunology and Immunology and Allergy. According to data from OpenAlex, Kenji Kabashima has authored 483 papers receiving a total of 22.4k indexed citations (citations by other indexed papers that have themselves been cited), including 280 papers in Dermatology, 187 papers in Immunology and 132 papers in Immunology and Allergy. Recurrent topics in Kenji Kabashima's work include Dermatology and Skin Diseases (221 papers), Allergic Rhinitis and Sensitization (109 papers) and Asthma and respiratory diseases (88 papers). Kenji Kabashima is often cited by papers focused on Dermatology and Skin Diseases (221 papers), Allergic Rhinitis and Sensitization (109 papers) and Asthma and respiratory diseases (88 papers). Kenji Kabashima collaborates with scholars based in Japan, Singapore and United States. Kenji Kabashima's co-authors include Atsushi Otsuka, Gyohei Egawa, Tetsuya Honda, Yoshiki Miyachi, Y. Tokura, Judith A. Seidel, Thomas Bieber, Takashi Nomura, Shuh Narumiya and Saeko Nakajima and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Kenji Kabashima

460 papers receiving 22.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atopic dermatitis

2018 1.1k citations Kenji Kabashima et al. profile →
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

2018 1.0k citations Atsushi Otsuka, Kenji Kabashima et al. profile →
Prostaglandin D ₂ as a Mediator of Allergic Asthma

2000 625 citations Toshiyuki Matsuoka, Tatsunori Murata et al. profile →
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

2010 537 citations Kenji Kabashima et al. profile →
Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis

2008 532 citations Kenji Kabashima et al. profile →
The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

2015 489 citations Saeko Nakajima, Tetsuya Honda et al. profile →
The immunological anatomy of the skin

2018 434 citations Kenji Kabashima, Tetsuya Honda et al. profile →
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis

2017 414 citations Andreas Wollenberg, Kenji Kabashima et al. profile →
Type 2 immunity in the skin and lungs

2020 375 citations Cezmi A. Akdiş, Peter D. Arkwright et al. Allergy profile →
The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis

2018 287 citations Teruki Dainichi, Akihiko Kitoh et al. profile →
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder

2016 281 citations Emma Guttman‐Yassky, Amy S. Paller et al. profile →
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

2021 250 citations Kristian Reich, Kenji Kabashima et al. profile →
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

2020 237 citations Kenji Kabashima, Hiroshi Komazaki et al. profile →
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

2021 200 citations Kenji Kabashima, Emma Guttman‐Yassky et al. profile →
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis

2022 139 citations Kenji Kabashima et al. SHILAP Revista de lepidopterología profile →
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

2022 99 citations Emma Guttman‐Yassky, Kristian Reich et al. profile →
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

2024 39 citations Kenji Kabashima, Andreas Wollenberg et al. profile →

Peers

Countries citing papers authored by Kenji Kabashima

Since Specialization

Citations

This map shows the geographic impact of Kenji Kabashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Kabashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Kabashima more than expected).

Fields of papers citing papers by Kenji Kabashima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Kabashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Kabashima. The network helps show where Kenji Kabashima may publish in the future.

Co-authorship network of co-authors of Kenji Kabashima

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Kabashima. A scholar is included among the top collaborators of Kenji Kabashima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Kabashima. Kenji Kabashima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of Prophylactic Topical Steroid Administration for Enfortumab Vedotin–related Cutaneous Toxicity 2024 ·European Urology Open Science ·(unknown), Takashi Nomura, Saeko Nakajima, Satoru Yonekura, (unknown), Takayuki Sumiyoshi, (unknown), Takayuki Goto, Ryoichi Saito, Kenji Kabashima, Takashi Kobayashi	1
2	Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials 2024 ·Pediatrics International ·Tatsuki Fukuie, (unknown), (unknown), Katsuyo Ohashi‐Doi, Kenji Kabashima	1
3	Notalgia Paresthetica Dermatologist Report of Symptom Burden and Treatment: Results from a Physician Survey 2024 ·Acta Dermato Venereologica ·Brian Kim, Sonja Ständer, Kenji Kabashima, Jennifer A. Mohawk, (unknown), Joana Gonçalves, Nilam C. Shah, Catherine Munera, Joseph C. Punzalan, (unknown), Mark Lebwohl	2
4	Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years 2024 ·Allergy ·Emma Guttman‐Yassky, Kenji Kabashima, D. Staumont‐Sallé, Walter K. Nahm, (unknown), Joel Corrêa da Rosa, (unknown), (unknown), Mads A. Røpke, (unknown), Louise Abildgaard Steffensen, Andrew Blauvelt, Kristian Reich	28
5	English version of Japanese guidance for biologics in treating atopic dermatitis 2023 ·The Journal of Dermatology ·Hidehisa Saeki, Masashi Akiyama, Masatoshi Abe, Atsuyuki Igarashi, Shinichi Imafuku, Yukihiro Ohya, Norito Katoh, Hideto Kameda, Kenji Kabashima, Yuichiro Tsunemi, Michihiro Hide, Mamitaro Ohtsuki	6
6	Atopic dermatitis: A global health perspective 2023 ·Journal of the European Academy of Dermatology and Venereology ·Ousmane Faye, Carsten Flohr, Kenji Kabashima, Lin Ma, Amy S. Paller, (unknown), Martin Steinhoff, John Su, Roberto Takaoka, Andreas Wollenberg, Yik Weng Yew, José A Ruiz-Postigo, Peter Schmid‐Grendelmeier, Alain Taı̈eb	30
7	Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial 2023 ·Dermatology and Therapy ·Kenji Kabashima, (unknown), Hiroshi Komazaki, Makoto Kawashima, (unknown)	9
8	Multiple Bowen's Disease on the Finger Associated with Human Papillomavirus Type 34 2023 ·SHILAP Revista de lepidopterología ·Satoru Yonekura, Gyohei Egawa, (unknown), Kenji Kabashima	3
9	Recurrent cutaneous squamous cell carcinoma in the occipital scalp with clinical perineural invasion developing jugular foramen syndrome 2023 ·JAAD Case Reports ·(unknown), Yo Kaku, (unknown), (unknown), Satoru Yonekura, Yoshiaki Yoshikawa, Kenji Kabashima	1
10	Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial 2023 ·Journal of Dermatological Treatment ·Kenji Kabashima, (unknown), (unknown), Makoto Kawashima, (unknown)	8
11	Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies 2023 ·Immunological Medicine ·Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima	5
12	Increased type I interferon expression from T cells in lesional skin of Degos disease 2023 ·The Journal of Dermatology ·(unknown), Atsushi Otsuka, Toshiaki Kogame, Hiroyuki Ito, (unknown), Masakazu Fujimoto, (unknown), Masahiro Hirata, Kazumitsu Sugiura, Kenji Kabashima	1
13	A Novel Virus Alters Gene Expression and Vacuolar Morphology in Malassezia Cells and Induces a TLR3-Mediated Inflammatory Immune Response 2020 ·mBio ·Minji Park, Yong‐Joon Cho, Dong-Gyu Kim, Chul‐Su Yang, (unknown), Thomas L. Dawson, Satoshi Nakamizo, Kenji Kabashima, Yang Won Lee, Won Hee Jung	28
14	Type 2 immunity in the skin and lungs breakdown → 2020 ·Allergy ·Cezmi A. Akdiş, Peter D. Arkwright, Marie‐Charlotte Brüggen, William W. Busse, Massimo Gadina, Emma Guttman‐Yassky, Kenji Kabashima, Yasutaka Mitamura, Laura Vian, Jianni Wu, Óscar Palomares	375
15	Accumulation of exhausted CD8+ T cells in extramammary Paget’s disease 2019 ·PLoS ONE ·(unknown), Atsushi Otsuka, Yosuke Yamamoto, Chisa Nakashima, Tetsuya Honda, Akihiko Kitoh, Saeko Nakajima, Gyohei Egawa, Takashi Nomura, Teruki Dainichi, Shigeto Matsushita, Hideaki Tanizaki, Yuki Yamamoto, Takeru Funakoshi, Yasuhiro Fujisawa, Taku Fujimura, Hiroo Hata, Yoshihiro Ishida, Kenji Kabashima	11
16	CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia 2018 ·Clinical Cancer Research ·Masahiko Ajiro, Hiroyuki Sakai, Hiroshi Onogi, Makoto Yamamoto, Eriko Sumi, (unknown), Takashi Nomura, Kenji Kabashima, Takamitsu Hosoya, Masatoshi Hagiwara	30
17	The role of basophils and proallergic cytokines, TSLP and IL-33, in cutaneously sensitized food allergy 2014 ·International Immunology ·Taichiro Muto, Ayumi Fukuoka, Kenji Kabashima, Steven F. Ziegler, Kenji Nakanishi, Kazufumi Matsushita, Tomohiro Yoshimoto	94
18	Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism 2006 ·The Journal of Experimental Medicine ·Kenji Kabashima, Nicole M. Haynes, Ying Xu, Stephen L. Nutt, María L. Allende, Richard L. Proia, Jason G. Cyster	167
19	The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut 2002 ·Journal of Clinical Investigation ·Kenji Kabashima, (unknown), Tatsunori Murata, (unknown), Toshiyuki Matsuoka, Eri Segi‐Nishida, Kazuhito Tsuboi, Yukihiko Sugimoto, Takuya Kobayashi, Yoshiki Miyachi, Atsushi Ichikawa, Shuh Narumiya	371
20	The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut 2002 ·Journal of Clinical Investigation ·Kenji Kabashima, (unknown), Tatsunori Murata, (unknown), Toshiyuki Matsuoka, Eri Segi‐Nishida, Kazuhito Tsuboi, Yukihiko Sugimoto, Takuya Kobayashi, Yoshiki Miyachi, Atsushi Ichikawa, Shuh Narumiya	377

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact